 HOUSTON, March 02, 2022 GLOBE NEWSWIRE -- Aravive, Inc. Nasdaq: ARAV, a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research AACR annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana. The abstract presentation at AACR will be presented virtually. 